Org 21465

A discontinued Organon water-soluble steroid anaesthetic; a C2-morpholinyl GABA-A positive allosteric modulator abandoned after excitatory movements appeared in human volunteers.

Org 21465 was evaluated only in small phase 1 studies in healthy male volunteers and was never approved, marketed, or subjected to the wider safety characterisation expected of a clinical anaesthetic. The available human data document universal involuntary excitatory movements, universal venous pain on injection, and difficult titration owing to slow effect-site equilibration, alongside the reassuring absence of overt histamine release or respiratory depression at the doses tested. Because development was halted, there are no modern pharmacovigilance data, no established dosing, and no information on repeated exposure, drug interactions, or long-term effects. It is a historical research compound with no legitimate therapeutic or self-administration role, and it should be regarded strictly as an item of pharmacological interest rather than a usable drug.

Org 21465 emerged from Organon's long-running search for a practical steroid anaesthetic, a line of research that stretches back to the introduction of the first steroid hypnotics and the clinically successful but vehicle-troubled alphaxalone (a component of Althesin). Earlier water-soluble candidates such as minaxolone had reached human testing in the late 1970s and early 1980s before being abandoned, and interest later shifted to pregnanolone (eltanolone).

In the 1990s medicinal chemists at Organon Laboratories in Scotland synthesised a series of 2-beta-morpholinyl pregnane steroids, formulated as methanesulphonate salts, to achieve genuine aqueous solubility while preserving neurosteroid-like GABA-A activity; Org 20599 and Org 21465 were the notable candidates from this effort.

Org 21465 was administered to human volunteers in studies published in the British Journal of Anaesthesia in 1997, including a computer-controlled infusion characterisation, and an accompanying editorial questioned whether it represented a meaningful advance. The excitatory movements and other liabilities seen in those trials led to its discontinuation, and it is now cited chiefly in reviews cataloguing the repeated, largely unsuccessful attempts to bring a steroid anaesthetic to market.

Within pharmacology Org 21465 is a niche, historical footnote rather than a compound of ongoing interest. It is remembered mainly as a companion to Org 20599 in Organon's water-soluble morpholinyl steroid programme and as a case study in why neurosteroid GABA-A pharmacology, despite its elegance, has proven so hard to convert into a clinically acceptable intravenous anaesthetic. It carries no reputation as a nootropic or recreational agent, has no consumer following, and appears almost exclusively in specialist anaesthesia and neurosteroid literature and in reviews of discontinued steroid hypnotics.